JP2021521794A5 - - Google Patents
Info
- Publication number
- JP2021521794A5 JP2021521794A5 JP2020557910A JP2020557910A JP2021521794A5 JP 2021521794 A5 JP2021521794 A5 JP 2021521794A5 JP 2020557910 A JP2020557910 A JP 2020557910A JP 2020557910 A JP2020557910 A JP 2020557910A JP 2021521794 A5 JP2021521794 A5 JP 2021521794A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- antisense oligomer
- acceptable salt
- exon
- dystrophin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023202664A JP2024009344A (ja) | 2018-04-26 | 2023-11-30 | 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862663162P | 2018-04-26 | 2018-04-26 | |
| US62/663,162 | 2018-04-26 | ||
| PCT/US2019/028613 WO2019209764A2 (en) | 2018-04-26 | 2019-04-23 | Exon skipping oligomers and oligomer conjugates for muscular dystrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023202664A Division JP2024009344A (ja) | 2018-04-26 | 2023-11-30 | 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021521794A JP2021521794A (ja) | 2021-08-30 |
| JP2021521794A5 true JP2021521794A5 (enExample) | 2022-04-25 |
Family
ID=68295765
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020557910A Pending JP2021521794A (ja) | 2018-04-26 | 2019-04-23 | 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート |
| JP2023202664A Pending JP2024009344A (ja) | 2018-04-26 | 2023-11-30 | 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023202664A Pending JP2024009344A (ja) | 2018-04-26 | 2023-11-30 | 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20210102205A1 (enExample) |
| EP (1) | EP3784248A4 (enExample) |
| JP (2) | JP2021521794A (enExample) |
| WO (1) | WO2019209764A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2022171972A1 (en) * | 2021-02-12 | 2022-08-18 | Oxford University Innovation Limited | Cell-penetrating peptide conjugates and methods of their use |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2933332A1 (en) * | 2004-06-28 | 2015-10-21 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| BR122020021379B1 (pt) * | 2008-10-24 | 2021-05-11 | Sarepta Therapeutics, Inc. | oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular |
| TWI541024B (zh) * | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| CA3092114A1 (en) * | 2011-05-05 | 2012-11-08 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| CN103998458B (zh) * | 2011-08-30 | 2018-10-09 | 医学研究理事会 | 具有中央疏水域的细胞穿透肽 |
| HK1216902A1 (zh) * | 2012-12-20 | 2016-12-09 | Sarepta Therapeutics, Inc. | 用作治疗肌肉萎缩的改进外显子跳跃组合物 |
| US20140315977A1 (en) * | 2013-03-14 | 2014-10-23 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| US20140329762A1 (en) * | 2013-03-15 | 2014-11-06 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| EP3262056A4 (en) * | 2015-02-27 | 2018-09-19 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| EP3858993A1 (en) * | 2015-10-09 | 2021-08-04 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
| BR112018074346B1 (pt) * | 2016-05-24 | 2023-01-03 | Sarepta Therapeutics, Inc. | Composto oligomérico e processo para preparar um composto oligomérico |
| JP2019525742A (ja) * | 2016-06-30 | 2019-09-12 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーに対するエクソンスキッピングオリゴマー |
-
2019
- 2019-04-23 JP JP2020557910A patent/JP2021521794A/ja active Pending
- 2019-04-23 EP EP19793325.2A patent/EP3784248A4/en active Pending
- 2019-04-23 WO PCT/US2019/028613 patent/WO2019209764A2/en not_active Ceased
- 2019-04-23 US US17/048,163 patent/US20210102205A1/en not_active Abandoned
-
2023
- 2023-11-30 JP JP2023202664A patent/JP2024009344A/ja active Pending
-
2024
- 2024-04-12 US US18/634,360 patent/US20250092393A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521794A5 (enExample) | ||
| JP2020503010A5 (enExample) | ||
| JP2020503009A5 (enExample) | ||
| JP2021526017A5 (enExample) | ||
| JP2020511943A5 (enExample) | ||
| JP2021503941A5 (enExample) | ||
| US10190117B2 (en) | Double-stranded antisense nucleic acid with exon-skipping effect | |
| JP2020503049A5 (enExample) | ||
| JP2018518201A5 (enExample) | ||
| JP2025509438A5 (enExample) | ||
| EP3661563A1 (en) | Biomimetic nanomaterials and uses thereof | |
| JP2021511038A5 (enExample) | ||
| JP2018527013A5 (enExample) | ||
| JP2017505623A5 (enExample) | ||
| JP2010505741A5 (enExample) | ||
| JP2018513682A5 (enExample) | ||
| JP2023511991A5 (enExample) | ||
| JP2012506703A5 (enExample) | ||
| TW201625274A (zh) | 反義核酸 | |
| RU2015100198A (ru) | Хиральный адъювант нуклеиновой кислоты | |
| JP2022536495A5 (enExample) | ||
| US8722640B2 (en) | Stabilized STAT3 decoy oligonucleotides and uses therefor | |
| JP2019529406A5 (enExample) | ||
| JP2022533421A5 (enExample) | ||
| JP2013537404A5 (enExample) |